{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:11:06Z","timestamp":1791695466545,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ophtha.2014.07.002","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T16:24:07Z","timestamp":1408724647000},"page":"2473-2481","source":"Crossref","is-referenced-by-count":263,"title":["A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct00473330","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00473382","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01298076","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mark C.","family":"Gillies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndell L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey J.","family":"Quin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wedad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Aroney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.07.002_bib1","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(98)96025-0","article-title":"The 14-year incidence of visual loss in a diabetic population","volume":"105","author":"Moss","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2014.07.002_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ajo.2013.11.012","article-title":"Management paradigms for diabetic macular edema","volume":"157","author":"Mitchell","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.07.002_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib5","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2014.07.002_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/2013.jamaophthalmol.91","article-title":"Ranibizumab for Edema of the Macula in Diabetes Study: 3-year outcomes and the need for prolonged frequent treatment","volume":"131","author":"Do","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.07.002_bib7","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Diabetic Retinopathy Clinical Research Network","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib9","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","article-title":"A\u00a02-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-months data: report 3","volume":"130","author":"Rajendram","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.07.002_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ophtha.2011.02.045","article-title":"A\u00a0phase 2\/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema","volume":"118","author":"Sultan","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial","volume":"113","author":"Gillies","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib14","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.ophtha.2009.04.049","article-title":"Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema","volume":"116","author":"Gillies","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ophtha.2010.09.029","article-title":"Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial","volume":"118","author":"Gillies","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.07.002_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.07.002_bib18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2014.07.002_bib19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization: promises and potential problems","volume":"293","author":"van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2014.07.002_bib20","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1167\/iovs.06-0220","article-title":"The Impact of Vision Impairment Questionnaire: an evaluation of its measurement properties using Rasch analysis","volume":"47","author":"Lamoureux","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.07.002_bib21","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1167\/iovs.06-0610","article-title":"The effectiveness of low-vision rehabilitation on participation in daily living and quality of life","volume":"48","author":"Lamoureux","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.07.002_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jcrs.2007.12.052","article-title":"Validity of a visual impairment questionnaire in measuring cataract surgery outcomes","volume":"34","author":"Pesudovs","year":"2008","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.ophtha.2014.07.002_bib23","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1167\/iovs.10-7127","article-title":"The impact of vision impairment on vision-specific quality of life in Germany","volume":"52","author":"Finger","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2014.07.002_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2307\/2531734","article-title":"Models for longitudinal data: a generalized estimating equation approach","volume":"44","author":"Zeger","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.ophtha.2014.07.002_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2014.07.002_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02296272","article-title":"A\u00a0Rasch model for partial credit scoring","volume":"47","author":"Masters","year":"1982","journal-title":"Psychometrika"},{"key":"10.1016\/j.ophtha.2014.07.002_bib27","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00417-008-0928-y","article-title":"Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection","volume":"246","author":"Song","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.07.002_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/eye.2013.242","article-title":"Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results","volume":"28","author":"Kriechbaum","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2014.07.002_bib30","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","article-title":"Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema","volume":"120","author":"Callanan","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib31","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.07.002_bib32","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014005867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014005867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T06:58:31Z","timestamp":1538290711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014005867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0161642014005867"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.002","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}